![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
In #ClinicalTrial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: https://bit.ly/EA7222 #sarcomaawareness
Do you have squamous cell carcinoma of the head and neck that has spread to a limited number of places? If so, you may be eligible to participate in this study of a potential new treatment. Learn more: https://bit.ly/ea3211-study #HeadAndNeckCancer #HNSCC
Do you have #Cancer (any form of #SolidTumor) that has been recently diagnosed, and a new prescription for cancer medication? If so, you may be able to participate in a research study that aims to reduce #FinancialHardship. More info here: https://bit.ly/EAQ222CD
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
38
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
